Mass tort looks, from the outside, like a game for the biggest firms in the country. National advertising, dockets in the thousands, settlements with a lot of zeros. So smaller firms either stay out entirely or make the opposite mistake: they spread a modest budget across four or five litigations at once and end up with a thin slice of each and a real position in none.
There is a middle path, and it starts with a discipline successful firms in this space quietly share: they started with one tort. If you are evaluating mass tort leads for the first time, the question is not how many litigations you can touch. It is which single litigation deserves your first serious test, and how you will judge whether the test worked.
Why one tort beats five
Every litigation has its own eligibility criteria, its own claimant profile, its own timeline, and its own paperwork. Running one campaign means your intake team learns one set of criteria deeply: which diagnoses count, which timeframes matter, which facts disqualify a claimant. Running five campaigns at once means five shallow learning curves, five sets of screening questions, and a budget split so many ways that no single campaign generates enough cases to tell you anything useful.
One tort also keeps the math honest. With a single campaign, you know exactly what you spent, what arrived, and what signed.
Start with the stage of the litigation
The single biggest factor in picking your first tort is where the litigation sits in its life cycle.
A mature litigation has been running for years. The science has been argued, bellwether trials may have happened, and the path toward resolution is partly visible. Claimant volume is usually larger, and criteria are well defined because the docket has already sorted out which cases count. The tradeoff is competition: established firms are already there, and much of the claimant population may already have been reached.
An emerging docket is earlier and riskier. Criteria are still settling, filing windows and court structures are still taking shape, and nobody can promise how the litigation develops. The offsetting advantage is that early firms build a docket before the crowd arrives, and a claimant signed early is a claimant a competitor does not get later.
Neither stage is automatically right. A firm that needs cases producing fees sooner usually leans mature. A firm with patience and a longer runway can accept emerging docket risk in exchange for position. What matters is choosing the stage on purpose, not drifting into whichever tort a salesperson mentioned last.
A concrete contrast helps. Roundup is a mature litigation with well established criteria and a long public history. Depo-Provera is a newer litigation, where the docket is still forming and the criteria conversation is more current.
A quick stage selection matrix
Score each factor for your firm, not for the market in general.
| Factor | Emerging docket | Mature litigation |
|---|---|---|
| Criteria clarity | Still settling; expect revisions | Established and easier to screen |
| Claimant availability | Harder to estimate | Easier to scope |
| Competition | Fewer settled firms | More firms already active |
| Timeline visibility | More open questions | Clearer path and milestones |
| Team learning | Playbook changes as criteria firm up | Steadier playbook |
| Best fit | Longer runway; tolerates uncertainty | Needs clear benchmarks |
One hard constraint can outweigh the rest. A short filing runway can rule out an emerging docket. Heavy competition in a mature litigation may be manageable if your geography or criteria give you a defined niche. Write down the reason for your choice.
Budget against the calendar, not just the campaign
Mass tort pricing is campaign specific. There is no honest price list, because the cost of finding a qualified claimant depends on the tort, the strictness of the criteria, and the geography. Anyone who quotes you a flat per lead figure without asking about your criteria first is guessing with your money.
So budget in a different way. Your spend has to survive long enough to produce a judgeable result: enough signed cases to know your real cost per signed case. Filing windows and statute deadlines matter here too. A budget that runs out the month before a key filing window closes is a budget spent at the worst possible time. Ask about the calendar before you commit, and size the test so it reaches a conclusion.
Criteria: strict is not the same as smart
New buyers often ask for the tightest possible criteria, assuming tighter means better. Tighter means fewer. Every requirement you add on diagnosis, timeframe, treatment, or documentation shrinks the pool of qualifying claimants, raises the cost of finding each one, and slows the campaign. Criteria should match what your firm will actually sign and work, no looser and no stricter. If your firm would sign a case with a confirmed diagnosis and a documented exposure history, do not demand records at the lead stage that the litigation itself does not require until later.
Fill in this planning worksheet before you call a provider
Answer these eight lines in plain language before asking for a scope.
- Tort and stage: Which litigation, and is it emerging or mature?
- Claimant profile: What diagnosis, exposure, and timeframe facts must be present?
- Clear exclusions: Which facts mean an automatic decline?
- Geography: Which states will you accept, and which are excluded?
- Proof at intake: What must be known on the first call, and what can come later?
- Intake owner: Who works each inquiry, how quickly, and how often?
- Signing path: Who reviews borderline cases, and will your firm or a co-counsel partner sign?
- Test limit and review date: How much spend is approved, and when will you judge it?
Fill every blank before money moves. A blank on exclusions becomes a quality dispute. A blank on ownership becomes unworked inquiries. A blank on the review date becomes a campaign that drifts.
Leads or signed cases: match the product to your intake bench
A lead still needs your team to call, qualify, and sign the claimant. A signed case arrives with that work done. Which one fits depends on a question only you can answer: does your firm have the intake capacity to work mass tort inquiries properly, including follow up, or will those leads sit behind your existing caseload?
If you have staff who can work a new practice area’s intake with real attention, leads give you a lower cost per inquiry and more control. If your team’s week is already spoken for, signed cases on select campaigns cost more per case and remove the conversion risk. Be honest about the bench you have today, not the one you plan to hire.
The co-counsel option
There is a third route that smaller firms overlook. Co-counsel arrangements let your firm hold a share of a docket while an established mass tort firm carries the litigation work: the filings, the science, the bellwether process. You bring the clients and the client relationship; the co-counsel firm brings the infrastructure a single litigation demands. It is a sensible way to participate in a tort your firm could not litigate alone, and it changes the buying decision, because the partner firm’s standards partly set your criteria. If co-counsel is your likely route, decide that before you buy, not after the first cases arrive.
A sensible sequence for your first campaign
- Pick one tort. Choose the stage deliberately, emerging or mature, based on your runway and your risk tolerance.
- Define your criteria in writing. Match them to what your firm, or your co-counsel partner, will actually sign.
- Run a scoped test campaign. Size it to produce a judgeable number of signed cases, with scope and geography agreed before money moves.
- Judge cost per signed case, not cost per lead. A cheap lead that never signs is the most expensive lead you bought. Count signed cases against total spend.
- Then expand. Add volume to the tort that proved itself, or apply the same discipline to a second tort with real data behind the decision.
A simple 30 to 60 to 90 day test plan
Days 1 to 30: set up and learn. Finalize the criteria sheet, intake script, and outcome categories. Review each delivery against the signing standard. The goal is to find misunderstandings early, while they are still cheap to correct.
Days 31 to 60: judge patterns, not anecdotes. Track how many inquiries matched the profile, how many your team reached, how many signed, and what total spend produced per signed case. Sort misses by cause: criteria fit, slow follow up, narrow geography, or unconfirmed documentation. Fix one variable at a time.
Days 61 to 90: decide on evidence. Compare the outcome with your prelaunch worksheet. If the facts no longer match your assumptions, decide from the new facts.
Decision rules for expanding, pausing, or switching
Expand when signed cases meet your criteria, the cost per signed case works, and your team can absorb more volume without follow up slipping. Increase in a controlled step, then check quality again.
Pause when delivery is too thin to judge, the calendar shifts, criteria change midstream, or an intake backlog means new claimants would be worked badly. Set the restart condition before you pause.
Switch torts when deliveries keep missing the agreed profile after criteria and follow up problems have been corrected, or the calendar leaves too little runway. Do not switch because another litigation is being promoted harder. A switch restarts the learning curve, so write down a reason strong enough to justify that cost.
The bottom line
Smaller firms do not lose at mass tort because they are small. They lose when they spread thin and never run one campaign long enough to learn what it actually produces. One tort, chosen on purpose, tested at a sensible size, and judged on signed cases is a strategy a firm of almost any size can run. When you are ready to scope that first test, start with how mass tort campaigns are built around a single litigation and bring your criteria with you. The conversation will be shorter and the answer will be straighter.
